Prix
GRAPH PAR
Questions fréquentes
Quelle est la capitalisation boursière de Unicycive Therap ?
Quel est le bénéfice par action (BPA) de Unicycive Therap ?
Quelles sont les évaluations des analystes et le prix cible de l'action Unicycive Therap ?
Quel est l'EBITDA de Unicycive Therap ?
Quel est le flux de trésorerie disponible de Unicycive Therap ?
Combien d'employés compte Unicycive Therap, et à quel secteur d'activité appartient-elle ?
Quel est le flottant des actions de Unicycive Therap ?
Finances
- Capitalisation boursière
- 133,71 M $US
- BPA (TTM)
- -1,596 $US
- Free Float
- 26,62 M
- EBITDA (TTM)
- -32,48 M $US
- Cash-flow disponible (TTM)
- -27,85 M $US
Cotation
- 52W span
- 3,72 $US8,74 $US
Notes des analystes
L'objectif de prix est de 29,60 $US et l'action est analysée par 10 analystes.
Acheter
10
Hold
0
Vendre
0
Informations
Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.
- Salariés
- 21
- Industries
- Biotechnologie
- Secteur
- Soins de santé
Identifiant
- Ticker primaire
- UNCY